Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery

University Hospitals (UH)

Status and phase: Completed; Phase 3

Conditions: Postoperative Complications; Pain, Postoperative; Opioid Use; Meniscus Tear, Tibial; Ketorolac Adverse Reaction

Treatments: Drug: Oxycodone-Acetaminophen; Drug: Ketorolac

Study type: Interventional

Funder types: Other

Identifiers

NCT04246541

STUDY20181100

Details and patient eligibility

About

The utilization of arthroscopic surgery to treat meniscus injuries has continued to increase in recent years, partly due to a younger, more active population, and improved technology and technique. However, pain management in the post-operative period is critical to the ability to perform this procedure as an outpatient surgery. Traditionally, oral narcotic agents have been the preferred analgesic postoperatively in orthopaedic surgery. However, these agents are associated with several side effects, including nausea/vomiting, constipation, and somnolence. In addition, opioid agents have a significant potential for abuse in comparison to non-narcotic analgesics. In light of the rising opioid epidemic and nationwide initiatives to limit narcotic usage, surgeons must explore alternate pain modalities in the acute postoperative period. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties.1 Multiple prior studies have examined the beneficial effect of oral and intravenous (IV) ketorolac as an analgesic in the postoperative period,1-3 including arthroscopic meniscus surgery. However, the beneficial effects of this agent following arthroscopic meniscus surgery have not been extensively described.

Enrollment: 48 patients

Sex: All

Ages: 18 to 89 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients between 18 and 89 years of age
• Patients undergoing primary arthroscopic meniscus surgery

Exclusion criteria

• Patients age less than 18 or greater than 89 years
• Illiterate or non-English speaking patients
• Patients with contraindications to ketorolac
• History of drug or alcohol abuse
• Chronic use of analgesic or psychotropic drugs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

48 participants in 2 patient groups

Control

Experimental group

Description:

Patients will receive standard of care Percocet for post-operative pain control following meniscus debridement surgery

Treatment:

Drug: Oxycodone-Acetaminophen

Ketorolac

Experimental group

Description:

Patients will receive IV ketorolac during surgery. They will then receive 3 days of oral ketorolac every 6 hours for pain control following surgery.

Treatment:

Drug: Ketorolac